Chyn C

Haematology. Blood Cancers. Acute Leuk. AML MDS.

[Georgia McCaughan @gjmccaughan]

Congratulations @jadothm on your abstract at #ASH24 examining outcomes in intensively treated AML with KMT2A rearrangements
Intensified induction with FLAG-Ida improved MRD clearance and reduced relapse
Molecular MRD after course 2 was a strong predictor of survival

[Australasian Leukaemia & Lymphoma Group (ALLG) @ALLGtrials]

Congratulations to ALLG member Dr Chyn Chua who has just completed her podium presentation at ASH 2024 on the trial results of the ALLG AMLM25 INTERVENE, which aims to increase survival rates for people aged >60 with AML. Visit https://t.co/HwP87B4c7y.

[Diva @Diva_Baggio]

Congratulations @drchynchua - wonderful to see this work of @ALLGtrials highlighted.

[Australasian Leukaemia & Lymphoma Group (ALLG) @ALLGtrials]

Abstracts accepted at the American Society of Hematology conference meeting ASH 2024 are considered the best out of thousands submitted worldwide and represent high impact and groundbreaking novel research in the field.

Visit, https://t.co/PhLlpXEFnY for more info.

[Chyn C @drchynchua]

What do people usually have for breakfast during #ASH24?

[Jake Shortt @JakeShortt3]

Congratulations to Dr Emma Leitinger and our anticoagulant stewardship team @MonashHealth as finalists in the 2024 Victorian Public Healthcare Awards. Making anticoagulants safer for our >2000 inpatients is no mean feat!

[Keith W Pratz MD @PratzKW]

Happy to share novel risk signature for AML treated with Azacitidine and Venetoclax. These data derived from VIALE-A trial demonstrate mutations in four genes (TP53, FLT-3, KRAS, & NRAS) predict patient outcomes more definitively than ELN2022 or ELN 2017. https://t.co/wbO29sU1IE

[Jake Shortt @JakeShortt3]

Great to be part of an amazing Haem Team raising $$ for our Foundation ⁦@MonashHealth⁩ in RunMelbourne today. Thanks to all our supporters and donors ⁦@DrGarethGregor1⁩ ⁦@drchynchua⁩

[Gareth Gregory @DrGarethGregor1]

Thanks to those that contributed! 🙏 Great job by our team (some shown here) and a questionable pacer that pushed me to a PB! 🎉 @MonashHealth

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

What better way 2 begin the academic year than 2 learn the “16+2” molecular subgroups of #MDSsm …. Never a better time to be a #hematopathologist 🎉
Going frm 3 genetically defined groups (multi TP53, SF3B1 and del 5q) of MDS to 16 👇🏼is a major advancement in our understanding of MDS biology 💡
🙏🏻 and congratulations @Elsa2Bernard @PapaemmanuilLab and everyone involved for this beautiful and clinically important work!
@BloodJournal @ASH_hematology
#hemepath
https://t.co/bDImaSV2VD

[Anand Patel @Anand_88_Patel]

A helpful article diving into the nuance of KMTAr AML and outcomes!

-KRAS, TP53, or DNMT3A co-mutations with particularly poor outcomes

https://t.co/3EbEMQMsP5

[Chyn C @drchynchua]

We (Monash Haematology team) are running for Monash Haematology and will appreicate any support no matter how big or small! Proceeds will go to improving patient care and wellbeing 🫰🏻🫰🏻🫰🏻🙏🏻🙏🏻

https://t.co/GWTRLxmDUG

[Chyn C @drchynchua]

Come and join us at Monash Health in 2025 for an exciting journey and growth 📈

[Gareth Gregory @DrGarethGregor1]

We’re hiring! Research Fellows 2025 at Monash Health:
- Lymphoma / Cellular Therapies
- Myeloid Diseases
Come work with our fantastic team! @drchynchua @JakeShortt3 @erica_m_wood @OpatStephen and many more @SCSMonash

https://t.co/nTw93VvggB

[Gareth Gregory @DrGarethGregor1]

We’re hiring! Research Fellows 2025 at Monash Health:
- Lymphoma / Cellular Therapies
- Myeloid Diseases
Come work with our fantastic team! @drchynchua @JakeShortt3 @erica_m_wood @OpatStephen and many more @SCSMonash

https://t.co/nTw93VvggB

[WEHI (Walter and Eliza Hall Institute) @WEHI_research]

WEHI's Dr Sarah Diepstraten spoke with @10NewsFirstMelb about the novel combination of two cancer drugs that has shown great potential as a future treatment for patients with acute myeloid leukaemia (AML).

Watch the segment 👇

[Jake Shortt @JakeShortt3]

Congratulations Ross, Rory and Jacinta and well done ALLG for supporting this initiative. Great to have Ross on board in our trial unit @MonashHealth now

[Haematologica @Haematologica]

Machine learning methods: a new study examining validation of the European LeukemiaNet 2022 criteria and genomic clusters in older adults with #acute_myeloid_leukemia. https://t.co/xUn7hafh9W

[Vincent Rajkumar @VincentRK]

On being a good doctor.

The number of research publications don’t tell you how good a doctor is at being a doctor.

Neither do the number of book chapters or grants. Or academic rank.

It’s a different skill set.
Good doctors have stellar clinical acumen & empathy.
#MedTwitter

[Jake Shortt @JakeShortt3]

Timely piece on CLL survivorship by @OpatStephen and Pasquale Fedele @MonashHealth in the JCO https://t.co/wqBcrwHKfH

[Mehdi Hamadani, MD @MediHumdani]

1/x Much awaited @BMTCTN 1506 trial out in @JCO_ASCO establishing gilteritinib as SOC post #alloBMT maintenance in #MRD +ve FLT3-ITD #AML pts in CR1; thanks to a global collaboration funded by @AstellasUS @nih_nhlbi and @theNCI to @BMTCTN tweetorial👇
https://t.co/OD5B4yogDa